Kathy Bowdish

Dr. Bowdish joined PIC Therapeutics as its President & CEO in August 2020, bringing more than 20 years of biopharmaceutical business and scientific leadership to the company.

Kathy was most recently at Sanofi, where she launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early-stage pioneering science for patients' benefit, and more recently served as Vice President and Head of R&D Strategy.

Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Kathy’s positions include President & CSO, Permeon Biologics; President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.

Kathy has served on the Boards of Directors of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most recently as an Observer on the DiCE Molecules Board. Kathy received her Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons, and her B.Sc. degree in biology from the College of William and Mary.